Biocryst Pharmaceuticals Inc Contracts with Department of Health and Human Services
Relationship Overview
Total Contract Value: $301,278,095
Contract Count: 4
Average Contract Size: $75.3M
Sole Source Rate: 0%
Small Business Rate: 0%
Spending by Sector
- Other: $301.3M (4 contracts)
Contracts
- ADVANCE DEVELOPMENT OF NEW ANTIVIRAL AGENT FOR INFLUENZA — $205.0M
- IGF::OT::IGF - DEVELOPMENT OF MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES, BASE, OPTION 1 AND OPTION 2 AWARD, 09/16/2013 - 09/15/2017 — $47.8M
- PERAMIVIR, RAPIVAB FLU TREATMENT — $34.7M
- PERAMIVIR (RAPIVAB 200MG/20ML (10MG/ML INJ SOLN)) — $13.9M
Frequently Asked Questions
How many contracts does Biocryst Pharmaceuticals Inc have with Department of Health and Human Services?
Biocryst Pharmaceuticals Inc has 4 contracts with Department of Health and Human Services worth a combined $301.3M.
What is the average contract size between Biocryst Pharmaceuticals Inc and Department of Health and Human Services?
The average contract size is $75.3M.
What percentage of Biocryst Pharmaceuticals Inc's contracts with Department of Health and Human Services are sole-source?
0% of the contracts are sole-source awards.